RecruitingPhase 2NCT07268040

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

400 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Solid Tumors

Summary

This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BP102 Injection, a drug called Carboplatin injection, and others for people with malignant solid tumors. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-7787 Injection

SHR-7787 Injection.

DRUGSHR-1316 Injection

SHR-1316 Injection.

DRUGSHR-4849 Injection

SHR-4849 Injection.

DRUGEtoposide injection

Etoposide Injection.

DRUGCarboplatin injection

Carboplatin Injection.

DRUGCisplatin injection

Cisplatin Injection.

DRUGBP102 Injection

BP102 Injection.

Locations(2)

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07268040

Related Trials

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

NCT024213802 locations

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

NCT037398273 locations

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

NCT066295841 location

A Study of TAK-505 in Adults With Solid Tumors

NCT0743672815 locations

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

NCT070282811 location